Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: jeffbas who wrote (826)	4/20/1999 11:04:00 PM
From: scaram(o)uche	Read Replies (3) \| Respond to of 1073

Jeffrey: NRGN is a great company...... sound business plan, good scientists, snake bit. That's not a declining channel, that's an alley of misery. Penner has ushered in this house of drug death to take more molecules from promising trials to the garbage pail than any other CEO. So, why are they still alive and not a penny stock? Lots of cash at the correct time, respected science and management, and programs that have left them high on the [painful] learning curve. Yes, they give away much of their future to the partners. That's why we're so interested in the CRF program. It's "theirs and theirs alone". NRGN is a long-standing component of at least one of our portfolios..... probably "bounce". The company is also discussed, on occasion, in the "Ask Michael Burke" thread. Cheers! Rick